What are the Advantages of the Global Conjugate Vaccine Market?

A vaccine is a type of biological preparation that gives the body’s defense mechanism a boost against a particular disease or infection. It is usually made from the killed or weakened form of toxin, microbe and is designed to prevent a disease rather than treat it. Vaccines have saved millions of lives globally and continue to be one of the most significant public health interventions implemented in history.

In a conjugate vaccine, a weak antigen is attached to a strong antigen, therefore providing a strong immunological response to the weak antigen. According to research by a leading market research firm, the global conjugate vaccine market is anticipated to expand at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.

Vaccines fall under two main categories:

1.      Plain polysaccharide
2.      Conjugate polysaccharide

Plain polysaccharide vaccines combat diseases such as pneumococcal bacteria, meningococcal disease, and Hib. While these diseases are life-threatening and plain polysaccharide vaccines are effective in preventing them, still have some limitations.

1.      They have a short-lived impact
2.      People carry the bacteria for years without knowing and spread it to others.
3.      Maintain close contact with the carrier can increase the chance of contracting the disease by 800People carry times.

Conjugate vaccines have several advantages over plain polysaccharide vaccines.

1. Longer lasting and consistent protection when compared to a plain polysaccharide vaccine.
2. Reduction in number of bacteria carriers, hence reduction in the chance of spreading the illness.
3. Provides better protection to infants against life-threatening diseases.
4. When repeated doses are administered, there is a less chance of diminished immune response in the case of conjugate vaccines.

Despite the various advantages presented by the global conjugate vaccines market, there is limited availability of commercially usable conjugate vaccines due to the complex process involved in the conjugation of polysaccharides.

For more report please visit- Our Report Store
Contact No- +1-888-831-3350
Email id- ankita.basu@rogmreports.com
Contact person- Ankita Basu